Posts

Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

CTP-543 Phase 2 Alopecia Areata

Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress

-Concert Pharmaceuticals today announced that it will present results from its recently completed Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata. These data will be presented in the late breaking news session at the European Academy of Dermatology and Venereology (EADV) Annual Congress to be held October 9– 13, 2019 in Madrid, Spain.

The details of the presentation are as follows:

Title: CTP-543, an oral JAK inhibitor, achieves primary endpoint in Phase 2 randomized, placebo-controlled, dose ranging trial in patients with moderate-to-severe alopecia areata
Date and Time: Saturday, October 12, 2019 at 9:15 – 9:30 GMT
Session: Late-Breaking News Session
Room: Hall 10 Dali

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2 for the potential treatment of alopecia areata. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543 for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.

Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.

Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs.

The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress

Source

Previous Posts

Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

CTP-543 Phase 2 Alopecia Areata

Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress

-Concert Pharmaceuticals today announced that it will present results from its recently completed Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata. These data will be presented in the late breaking news session at the European Academy of Dermatology and Venereology (EADV) Annual Congress to be held October 9– 13, 2019 in Madrid, Spain.

The details of the presentation are as follows:

Title: CTP-543, an oral JAK inhibitor, achieves primary endpoint in Phase 2 randomized, placebo-controlled, dose ranging trial in patients with moderate-to-severe alopecia areata
Date and Time: Saturday, October 12, 2019 at 9:15 – 9:30 GMT
Session: Late-Breaking News Session
Room: Hall 10 Dali

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2 for the potential treatment of alopecia areata. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543 for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.

Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.

Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs.

The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress

Source

Previous Posts

Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

Concert Pharmaceuticals, Inc. today announced final topline results from its recently completed dose-ranging Phase 2 trial evaluating its investigational medicine CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss.

Patients treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary efficacy endpoint with statistically significant differences (p <0.001) relative to placebo in the percentage of patients achieving a ≥ 50% relative change from baseline at 24 weeks using the Severity of Alopecia Tool (SALT).

The 8 mg twice-daily and 12 mg twice-daily groups were also significantly different from placebo in the number of patients achieving ≥ 75% and ≥ 90% relative change in SALT from baseline at 24 weeks.

At Week 24, patients treated with 8 mg twice-daily and 12 mg twice-daily compared to placebo also rated significantly greater improvement in their alopecia areata on the Patient Global Impression of Improvement Scale. Treatment with CTP-543 was generally well tolerated. Complete study results are expected to be presented at a future medical meeting.

“We are very pleased with these clinical results and continue to believe CTP-543 has potential to be a best-in-class treatment for alopecia areata, a chronic dermatological autoimmune disease that currently has no approved therapies,” said James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals. “We are highly focused on the need for an effective and safe treatment for alopecia areata, and we plan to advance CTP-543 into Phase 3 testing next year.”

“These Phase 2 results of CTP-543, a Janus kinase or JAK inhibitor, for the treatment of patients with alopecia areata are highly encouraging,” stated Dr. Brett King, Associate Professor of Dermatology at Yale School of Medicine. “There is a growing body of evidence supporting JAKs as a target for the treatment of alopecia areata that is driving enthusiasm in dermatology to address an important unmet need for patients.”

The primary efficacy endpoint in the 12 mg twice-daily cohort was met with 58% of patients achieving a ≥ 50% relative reduction in their overall SALT score from baseline compared to 9% for placebo (p <0.001). In the 8 mg twice-daily cohort, 47% of patients achieved the primary endpoint compared to placebo (p <0.001).

For the 4 mg cohort, 21% of patients achieved a ≥ 50% relative reduction in their overall SALT score from baseline, however these differences were not significantly different from placebo. In addition, 78% of the patients receiving 12 mg twice-daily and 58% of the patients receiving 8 mg twice-daily rated their alopecia areata as “much improved” or “very much improved” at 24 weeks of dosing, a significant difference from placebo.

The average baseline SALT score across all patients was approximately 88%, where 0% is no scalp hair loss and 100% represents total scalp hair loss. The most common (≥10%) side effects in the 12 mg CTP-543 dose group were headache, nasopharyngitis, upper respiratory tract infection, and acne. One serious adverse event of facial cellulitis was reported as possibly related to treatment; however, after a brief interruption, treatment was continued and this patient completed the trial. No thromboembolic events were reported during the trial.

The Phase 2 trial was a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata. A total of 149 patients were randomized to receive one of three doses of CTP-543 (4 mg, 8 mg, or 12 mg) or placebo, administered twice-daily. The primary outcome measure utilized the SALT score after 24 weeks of dosing. All patients who completed 24 weeks of treatment in the 12 mg dosing cohort had the opportunity to continue in a separate extension study to evaluate long-term safety and efficacy of CTP-543.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK 1 and JAK 2 for the potential treatment of alopecia areata. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

Source

Previous Posts

Global Alopecia Treatment Market

Global Androgenic Alopecia Drug Market

Global Androgenic Alopecia Drug Market 2017 Industry, Analysis, Share, Growth, Sales, Trends, Supply, Forecast to 2022

This report studies the global Androgenic Alopecia Drug market status and forecast, categorizes the global Androgenic Alopecia Drug market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

The global Androgenic Alopecia Drug market is valued at  million US$ in 2017 and will reach  million US$ by the end of 2025, growing at a CAGR of  during 2018-2025.

The major manufacturers covered in this report

Allergan, Inc.
Histogen, Inc.
R-Tech Ueno, Ltd.
Hygeia Therapeutics, Inc.
SWITCH Biotech LLC
Polichem S.A.
Kasiak Research Pvt. Ltd.

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
North America
Europe
China
Japan
Southeast Asia
India

We can also provide the customized separate regional or country-level reports, for the following regions:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Rest of Asia-Pacific
Europe
Germany
France
UK
Italy
Spain
Russia
Rest of Europe
Central & South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Saudi Arabia
Turkey
Rest of Middle East & Africa

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
RK-023
Refagro
RCH-01
SM-04554
HYG-440
Others
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
Clinic
Hospital
Home Use

The study objectives of this report are:
To analyze and study the global Androgenic Alopecia Drug sales, value, status (2013-2017) and forecast (2018-2025).
Focuses on the key Androgenic Alopecia Drug manufacturers, to study the sales, value, market share and development plans in future.
Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
To define, describe and forecast the market by type, application and region.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Androgenic Alopecia Drug are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders

Androgenic Alopecia Drug Manufacturers
Androgenic Alopecia Drug Distributors/Traders/Wholesalers
Androgenic Alopecia Drug Subcomponent Manufacturers
Industry Association
Downstream Vendors

Available Customizations

With the given market data, QYResearch offers customizations according to the company’s specific needs. The following customization options are available for the report:
Regional and country-level analysis of the Androgenic Alopecia Drug market, by end-use.
Detailed analysis and profiles of additional market players.

 

Global Androgenic Alopecia Drug Market 2017 Industry, Analysis, Share, Growth, Sales, Trends, Supply, Forecast to 2022

Source

Previous Posts

Aclaris Therapeutics topical ATI-502

Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501

Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata

Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced results from its Phase 2 clinical trial of ATI-501 (AUAT-201 Oral), an investigational oral Janus Kinase (JAK) 1/3 inhibitor, in subjects with alopecia areata (AA).

Subjects treated with ATI-501 achieved statistically significant improvement over placebo in several measures of hair growth, including the primary endpoint and certain secondary endpoints of the trial.

AUAT-201 Oral, a Phase 2 randomized, double-blinded, parallel-group, placebo-controlled trial, evaluated the safety, efficacy, and dose response of three doses of ATI-501 on the regrowth of hair in 87 subjects with AA, including Patchy Alopecia, Alopecia Totalis, and Alopecia Universalis.

Subjects with 30% to 100% total scalp hair loss were randomized in a 1:1:1:1 ratio and received 24 weeks of treatment, twice daily, with either 400 mg, 600 mg or 800 mg of ATI-501 or a placebo oral suspension.

The primary endpoint of the trial was the mean percent change from baseline in the Severity of Alopecia Tool (SALT) score at week 24.

Subjects in each of the three ATI-501 active dose groups (400 mg, 600 mg, and 800 mg) had statistically significant improvements compared to placebo for the primary endpoint (p=0.011, p=0.001, and p=0.010, respectively).

Secondary endpoints for which subjects in all three active treatment arms of the trial also achieved statistically significant improvements at 24 weeks compared to placebo included the following:

  • Absolute change in SALT scores from baseline: p<0.05 for all three ATI-501 doses;
  • Alopecia Density and Extent (ALODEX) percent change from baseline: p<0.05 for all three ATI-501 doses; and
  • ALODEX absolute change from baseline: p<0.01 for all three ATI-501 doses

Other exploratory secondary endpoints which were assessed were not statistically significant compared to placebo.

ATI-501 was observed to be generally well-tolerated at all doses.  There were no serious adverse events reported. All adverse events (AEs) were mild or moderate in severity and rates of AEs were similar across all groups. No thromboembolic events were observed in the study.  The most common AEs across all groups were: nasopharyngitis, influenza, upper respiratory tract infection, urinary tract infection, acne, blood creatine phosphokinase increased, and sinusitis.  Two subjects in each of the placebo and 400 mg groups and one subject in the 600 mg group had AEs leading to discontinuation of study drug, with no such AEs in the 800 mg group.

“We are pleased with these results, and we thank the patients and the investigators who participated in this trial,” said Dr. David Gordon, the Chief Medical Officer of Aclaris.

Company to Host Conference Call

Management will conduct a conference call at 5:00 PM ET today to review these Phase 2 results and related matters.  The conference call will be webcast live over the Internet and can be accessed by logging on to the “Investors” page of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Aclaris Therapeutics website for 30 days following the call.

About Alopecia Areata

Alopecia Areata (AA) is an autoimmune dermatologic condition typically characterized by patchy non-scarring hair loss on the scalp and body.  More severe forms of AA include total scalp hair loss, known as alopecia totalis, and total hair loss on the scalp and body, known as alopecia universalis.  The scalp is the most commonly affected area. Onset of AA may occur in childhood and most patients experience onset by age 40. The course of disease is unpredictable and may involve spontaneous hair regrowth and sudden hair loss. Over half of patients with AA experience poor health-related quality of life. The disease can be associated with serious psychological consequences, including anxiety and depression. AA affects up to 1.8% of people in the United States and 2.0% of people globally at some point during their lives.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical company committed to addressing the needs of people with immuno-inflammatory and dermatological diseases who lack satisfactory treatment options.

The company’s diverse and multi-stage portfolio includes two FDA-approved medicines, one late-stage investigational medicine, and a pipeline powered by a robust R&D engine exploring protein kinase regulation. Aclaris Therapeutics’ active development programs focus on areas where significant treatment gaps exist, such as common warts, alopecia areata, and vitiligo.

For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn or Twitter @aclaristx.

Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata

Source

Previous Posts

Alopecia Treatment Market

Global Androgenic Alopecia Drug Market

Global Androgenic Alopecia Drug Market By Product Type (RK-023, Refagro) And By End-Users/Application (Clinic, Hospital) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 – 2026

Global Androgenic Alopecia Drug Market is accounted for xx USD million in 2019 and is expected to reach xx USD million by 2026 growing at a CAGR of xx% during the forecast period. The report offers in-depth insights, revenue details, and other vital information regarding the global Androgenic Alopecia Drug market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026.

Androgenic Alopecia Drug Market report covers size, share and forecast (value and volume) by regions, top players, product types and applications, with historical data along with forecast from 2019 to 2026; The report covers an in depth description, competitive scenario, wide product portfolio of key vendors and business strategy adopted by competitors along with their SWOT analysis, revenue, sales and Porter’s Five Forces Analysis.

By geography, this market has been segregated into five regions with revenue and growth rate of Androgenic Alopecia Drug from 2013 to 2026,

• North America  (U.S., Canada, Mexico)
• Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)
• Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)
• Latin America (Brazil, Rest of L.A.)
• Middle East And Africa(Turkey, GCC, Rest of Middle East)

The major players operating into Androgenic Alopecia Drug Market include:

Histogen kick starts clinical trial for female hair lossAllergan, Inc.
Histogen, Inc.
R-Tech Ueno, Ltd.
Hygeia Therapeutics, Inc.
SWITCH Biotech LLC
Polichem S.A.
Kasiak Research Pvt. Ltd.

This report segments the Global Androgenic Alopecia Drug Market as follows:

Global Androgenic Alopecia Drug Market: Type Segment Analysis
RK-023
Refagro
RCH-01
SM-04554
HYG-440
Others

Global Androgenic Alopecia Drug Market: Application Segment Analysis
Clinic
Hospital
Home Use

There are 13 chapters to put on view for Androgenic Alopecia Drug Market:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation overview
Chapter 2: Market competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Androgenic Alopecia Drug Research Findings and Conclusion, Appendix, methodology and data source

Data type include capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export have been determined using secondary sources and verified primary sources. Industry chain, manufacturing process, cost structure, marketing channel are also analyzed in this report.

Industry Chain Analysis

Raw Material and Suppliers
Equipment and Suppliers
Manufacturing Process
Manufacturing Cost Structure
Manufacturing Plants Distribution Analysis

Available Customizations

We can also provide customized report as per company’s specific needs. We can also provide the customized separate regional or country-level reports, for the specific region as per client requirement.

Global Androgenic Alopecia Drug Market

Source

Previous Posts

Global Hair Conditioner Industry Market Analysis

Global Hair Conditioner Industry Market Analysis

Global Hair Conditioner Industry Market Analysis & Forecast 2018-2023

In the Global Hair Conditioner Industry Market Analysis & Forecast 2018-2023, the revenue is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2023, growing at a CAGR of XX% between 2018 and 2023.

The production is estimated at XX million in 2017 and is forecasted to reach XX million by the end of 2023, growing at a CAGR of XX% between 2018 and 2023.
It covers Regional Segment Analysis, Type, Application, Major Manufactures, Industry Chain Analysis, Competitive Insights and Macroeconomic Analysis.

Global Hair Conditioner Market: Regional Segment Analysis

North America
Europe
China
Japan
Southeast Asia
India

The Major players reported in the market include:

company 1
company 2
company 3
company 4
company 5
company 6
company 7
company 8
company 9

Global Hair Conditioner Market: Product Segment Analysis

Type 1
Type 2
Type 3

Global Hair Conditioner Market: Application Segment Analysis

Application 1
Application 2
Application 3

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics
It provides a forward-looking perspective on different factors driving or restraining the market growth
It provides a six-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making an in-depth analysis of market segments


Global Hair Conditioner Industry Market Analysis & Forecast 2018-2023

Sources

Previous Posts

Male Androgenetic Alopecia

Global Alopecia Market Insights

Global Alopecia (Hair Loss Treatment) Market Insights, Forecast to 2025

The global Alopecia (Hair Loss Treatment) market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Alopecia (Hair Loss Treatment) market based on company, product type, end user and key regions.

This report studies the global market size of Alopecia (Hair Loss Treatment) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Alopecia (Hair Loss Treatment) in these regions.

This research report categorizes the global Alopecia (Hair Loss Treatment) market by top players/brands, region, type and end user. This report also studies the global Alopecia (Hair Loss Treatment) market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

Shiseido
Rohto
Unilever
Taisho
Angfa
LOreal
Kaminomoto
Merck
Yanagiya Honten
Amorepacific
Procter & Gamble
Himalaya
Gerolymatos International
Merz Pharma
Leader Teck
Vasu Healthcare
VLCC
Ales Group
Shanxi Ante
Wansheng Pharmaceutical
Advanced Skin and Hair
Humanwell Healthcare
Topfond
Lifes2good
Bawang
YNK Pharmaceutical
Apollo
Jingxiutang
Rogaine
Marico

Market size by Product

Shampoos and Conditioners
Medicine Product
Market size by End User
Men
Women

Market size by Region

North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:

To study and analyze the global Alopecia (Hair Loss Treatment) market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Alopecia (Hair Loss Treatment) market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Alopecia (Hair Loss Treatment) companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Alopecia (Hair Loss Treatment) submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Alopecia (Hair Loss Treatment) are as follows:

History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alopecia (Hair Loss Treatment) market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Global Alopecia (Hair Loss Treatment) Market Insights, Forecast to 2025

Source

Previous Posts

Alopecia Treatment Market

Global Alopecia Clinical Trial Pipeline Highlights – 2019

Global Alopecia Clinical Trial Pipeline Highlights – 2019

This report, Alopecia Pipeline Highlights – 2019, provides most up-to-date information on key pipeline products in the global Alopecia market. It covers emerging therapies for Alopecia in active clinical development stages including early and late stage clinical trials.

The pipeline data presented in this report helps executives in tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

 

Clinical Trial Stages:

The report provides Alopecia pipeline products by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Alopecia pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Alopecia pipeline products by the company.

Short-term Launch Highlights:

Find out which Alopecia pipeline products will be launched in the US and Ex-US to 2024.

Summary:

  • Alopecia phase 3 clinical trial pipeline products
  • Alopecia phase 2 clinical trial pipeline products
  • Alopecia phase 1 clinical trial pipeline products
  • Alopecia preclinical research pipeline products
  • Alopecia discovery stage pipeline products
  • Alopecia pipeline products short-term launch highlights

Global Alopecia Clinical Trial Pipeline Highlights – 2019

Source

Previous Posts

JAK inhibitor promotes hair growth

JAK inhibitor promotes hair growth

JAK inhibitor promotes hair growth in both men, women with androgenetic alopecia

Inflammation plays a key role in male and female pattern hair loss, Neal Walker, DO, president and CEO of Aclaris Therapeutics, said in an interview with Healio Dermatology regarding results from a phase 2 open-label clinical trial in subjects with androgenetic alopecia.

“Looking at the aggregate of the data, any way you looked at it was positive. If you look at target area hair count, the physicians’ global assessment or the subjects’ assessment, they all showed nice results,” Walker said.

The premise for this research came from Angela Christiano, PhD, and her lab at Columbia University.

“She discovered that JAK inhibitors seem to work by promoting the entry of the hair follicle back into the growth phase — the anagen phase,” Walker said. “In recent papers, she has published that part of that action is mediated by local inflammation. There are inflammatory cells that promote the hair follicle stem cell via the JAK signaling. It promotes a resting phase, which you might see clinically as hair loss.”

ATI-502 (Aclaris), an investigational topical Janus kinase (JAK) 1/3 inhibitor, was evaluated in adult women and men with androgenetic alopecia (AGA) and applied to the scalp twice daily for 26 weeks.

Twenty-three of 31 subjects completed 6 months of treatment. Twenty subjects, 14 men and 6 women, had evaluable hair counts, and 22 subjects recorded investigator global assessment and subject self-assessment scores.

The mean change from baseline in non-vellus target area hair count (TAHC) at week 26 was the primary endpoint. The TAHC increase was 15.3 hairs/cm2 in female subjects and 5.6 hairs/cm2 in males, according to a press release from Aclaris.

The investigators rated 16 of 22 subjects (73%) as experiencing increased hair growth, and 18 of 22 subjects (82%) rated themselves as experiencing increased hair growth.

“By inhibiting the local inflammation, you remove that [resting phase and hair loss effect], allowing hair follicle stem cell activation, pushing that follicle back into the anagen phase,” Walker said.

The effect in female subjects was particularly strong, according to Walker. A continued linear hair increase was seen up to 6 months, which is not typical in this condition, he said.

Twelve-month results from this trial are expected by the end of the year.

The treatment is nonhormonal, Walker said, and could be used in a variety of options, such as in monotherapy or in combination with existing therapies.

“One thing that surprised me was how robust the female data was,” Walker said. “ Most people who work in hair loss studies look at males first, then go to females. We just decided to do both. I think that was a pleasant surprise.”

As for the next step, Aclaris will initiate a double-blind, randomized controlled phase 2 dose-ranging clinical trial using higher concentrations of ATI-502 in the first half of 2020.

AGA is the most common form of hair loss, which affects approximately 50 million men and 30 million women in the U.S., according to the release.

“We found that inflammation, in fact, does play a key role in male/female pattern hair loss,” Walker said. “When we were in dermatology residency, that wasn’t dogma. There was a fringe number of dermatologists who thought that perhaps there was a role, but I think we’ve definitively shown that inflammation is a part of this process.” – by Abigail Sutton

JAK inhibitor promotes hair growth in both men, women with androgenetic alopecia

Source

Previous Posts

Alopecia Treatment Market

Alopecia Treatment Market

Alopecia (Hair Loss)Treatment Market: Global Industry Analysis and Forecast 2016 – 2022

Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues. A sedentary lifestyle and unhealthy diets are leading to loss of hair among masses.

Furthermore, ageing and hormonal imbalance, increasing chronic disease like arthritis, cancer, hypertension, depression also lead to hair loss, especially among the middle-aged population. According to the American Hair Loss Association, androgenetic alopecia accounts for over 95% of hair loss in men.

Over 800 thousand patients are seeking some kind of treatment for hair loss worldwide. For the treatment of alopecia, U.S. FDA proved two drugs – Minoxidil, to treat hypertension and finasteride (Propecia) to treat benign prostate hyperplasia (BPH).  The American Hair Loss Association recommends the use of minoxidil in patients who have not responded to finasteride treatment.

The prevalence rate of alopecia is high among working age population. Treatment seeking rate for alopecia is more prevalent in developed regions as compared to that in developing regions, however, over the past few years, demand for alopecia treatment has increased dramatically in developing regions such as China and India owing to increase in healthcare expenditure and improved healthcare infrastructure facilities.

In China, 6 percent of females and 21 percent of males suffer from hormone-driven hair loss.

Changing lifestyle along with an increase in stress level among the working-class population is expected to boost the demand for treatment of hair loss globally. Furthermore, the rise in geriatrics population along with high demand for surgical hair transplant is expected to drive the alopecia treatment market.

Increasing consumer disposable incomes and health awareness, emphasis to look good and technological advancement in hair treatment medical devices are some other key drivers for this market. Since accessibility for scalp treatment is easily accessible and available, the demand for alopecia treatment has increased.

Though the market is expected to witness healthy growth during the forecast period, high cost of the medications and possible side effects/allergic reactions are acting as a key barrier for alopecia market.

Alopecia Treatment Market is broadly classified on the basis of the following segments –

Alopecia Treatment Market by Product:

  • Vitamins and Supplements
  • Shampoos and Conditioners
  • Others (Serums, gels, and oils)

Alopecia Treatment Market by Gender:

  • Men
  • Women
  • Children

Alopecia Treatment Market by End User:

  • Homecare Settings
  • Dermatology Clinics
  • Others (Salons)

The alopecia treatment market has grown substantially at a healthy CAGR due to changing lifestyle and greater emphasis on outward appearance to look good. With rapid technological advancement and innovation, alopecia treatment market is expected to grow globally. North America is the largest market for alopecia treatment while the Asia Pacific is expected to be the fastest growing market during the forecast period.

The alopecia treatment market is expected to register a significant CAGR during the forecast period. Depending on geographic regions, alopecia treatment is segmented into seven key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America, followed by Europe, is expected to dominate the alopecia treatment market throughout the forecast period.

The Asia Pacific excluding Japan is poised to witness the fastest growth owing to outburst of the middle-aged population in the region. Also, the region is witnessing healthy growth in terms of GDP, which in turn is expected to propel growth at healthy digits. The Middle East & Africa and Latin America are expected to sluggish growth during the forecast period.

Some of the key market players for alopecia treatment market are Cipla, Viviscal, Dr. Reddy’s Laboratories Ltd., Regaine, Merck & Co., Inc, Ranbaxy Laboratories Ltd, Phyto – Alès Groupe, Kirkland Signature, Vitabiotics, Nanogen, Alpecin – Dr. Kurt Wolff GmbH & Co. KG, Rogaine – Johnson, and Johnson.

The report covers exhaustive analysis on:

  • Alopecia Treatment Market Segments
  • Alopecia Treatment Market Dynamics
  • Historical Actual Market Size, 2013 – 2015
  • Alopecia Treatment Market Size & Forecast 2016 to 2022
  • Alopecia Treatment Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Alopecia Treatment Market Drivers and Restraints

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • The Middle East and Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size
  • Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Alopecia (Hair Loss)Treatment Market: Global Industry Analysis and Forecast 2016 – 2022

Source

Previous Posts